ES2149253T3 - Medicamentos a base de acido docosahexaenoico como antiagregantes plaquetarios y contra las carencias cerebrales en acidos grasos esenciales y procedimientos de preparacion. - Google Patents

Medicamentos a base de acido docosahexaenoico como antiagregantes plaquetarios y contra las carencias cerebrales en acidos grasos esenciales y procedimientos de preparacion.

Info

Publication number
ES2149253T3
ES2149253T3 ES94900873T ES94900873T ES2149253T3 ES 2149253 T3 ES2149253 T3 ES 2149253T3 ES 94900873 T ES94900873 T ES 94900873T ES 94900873 T ES94900873 T ES 94900873T ES 2149253 T3 ES2149253 T3 ES 2149253T3
Authority
ES
Spain
Prior art keywords
essential fatty
antigregant
docosahexaenoic acid
fatty acids
preparation procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94900873T
Other languages
English (en)
Inventor
Yves Bayon
Martine Croset
Michel Lagarde
Jean Lecerf
Frank Thies
Jean-Louis Tayot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imedex SA
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Imedex SA
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imedex SA, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Imedex SA
Application granted granted Critical
Publication of ES2149253T3 publication Critical patent/ES2149253T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

NUEVOS MEDICAMENTOS A BASE DE ACIDOS GRASOS ESENCIALES, CARACTERIZADOS EN QUE COMPRENDEN UNA PROPORCION SUSTANCIAL DE ACIDO DOCOSAHEXAENOICO (DHA) EN LA CLASE DE ACIDOS GRASOS ESTERIFICADOS EN POSICION SN-2 DE LAS FOSFATIDICOLINAS (PDCHAS) ACETILADOS EN POSICION SN-1 O LISOFOSFATIDICOLINAS (LISO-PCDHA) O TRIGLICERIDOS-DHA ESTERIFICADOS EN POSICION SN-1 Y SN-3. ESTOS MEDICAMENTOS SE UTILIZAN PARA EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, INCLUIDO LA ENFERMEDAD ATEROMATOSA, Y EL DE LAS CARENCIAS O INSUFICIENCIA DE ACIDOS GRASOS ESENCIALES, PARTICULARMENTE CEREBRALES.
ES94900873T 1992-11-24 1993-11-24 Medicamentos a base de acido docosahexaenoico como antiagregantes plaquetarios y contra las carencias cerebrales en acidos grasos esenciales y procedimientos de preparacion. Expired - Lifetime ES2149253T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9214078A FR2698269B1 (fr) 1992-11-24 1992-11-24 Nouveaux médicaments à base d'acides gras insaturés, utilisables notamment comme antiagrégants plaquettaires et/ou comme transporteurs privilégiés vers le cerveau.
PCT/FR1993/001158 WO1994012170A2 (fr) 1992-11-24 1993-11-24 Medicaments a base d'acides gras polyinsatures, notamment d'acides docosahexaenoique comme antiagregants plaquettaires et contre des carences cerebrales en acides gras essentiels.

Publications (1)

Publication Number Publication Date
ES2149253T3 true ES2149253T3 (es) 2000-11-01

Family

ID=9435824

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94900873T Expired - Lifetime ES2149253T3 (es) 1992-11-24 1993-11-24 Medicamentos a base de acido docosahexaenoico como antiagregantes plaquetarios y contra las carencias cerebrales en acidos grasos esenciales y procedimientos de preparacion.

Country Status (10)

Country Link
US (1) US5654290A (es)
EP (1) EP0623019B1 (es)
JP (1) JPH07503488A (es)
AT (1) ATE192647T1 (es)
CA (1) CA2128706C (es)
DE (1) DE69328618T2 (es)
DK (1) DK0623019T3 (es)
ES (1) ES2149253T3 (es)
FR (1) FR2698269B1 (es)
WO (1) WO1994012170A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
WO2002076402A2 (en) 2001-03-23 2002-10-03 Protarga, Inc. Fatty amine drug conjugates
JP4634694B2 (ja) 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
IL142952A (en) * 2001-05-03 2005-12-18 Enzmotec Ltd Process for enzyme-catalyzed production of 1,2 diacylated phospholipids
EP1466597A1 (en) * 2003-04-07 2004-10-13 Clinigenetics Use of dha esters to control or prevent cardiovascular diseases
FR2857265A1 (fr) * 2003-07-08 2005-01-14 Clinigenetics Utilisation de lyso-pcdha pour le traitement des maladies cardiovasculaires
WO2004091603A1 (fr) * 2003-04-07 2004-10-28 Clinigenetics Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
JPWO2005061684A1 (ja) * 2003-12-22 2007-12-13 湧永製薬株式会社 油脂組成物
JP5352961B2 (ja) * 2006-03-28 2013-11-27 Ｊｎｃ株式会社 生活習慣病予防・治療剤
FR2979825B1 (fr) 2011-09-13 2013-11-29 Inst Nat Sciences Appliq Phosphatidylcholines specifiques en tant que modulateurs de l'activite du facteur d'activation plaquettaire
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
MX2020006529A (es) 2017-12-21 2021-01-08 Aker Biomarine Antarctic As Composiciones de lisofosfatidilcolina.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2098065A (en) * 1981-04-14 1982-11-17 Nippon Suisan Kaisha Ltd Antithrombotic compositions containing docosahexaenoic acid
IT1223290B (it) * 1987-07-27 1990-09-19 Indena Spa Acidi poliinsaturi ad azione vasocinetica e relative formulazioni farmaceutiche e cosmetiche
JPS6450890A (en) * 1987-08-20 1989-02-27 Nippon Oils & Fats Co Ltd Production of docosahexaenoic acid-containing phosphatidyl choline
JP2537645B2 (ja) * 1987-11-13 1996-09-25 雪印乳業株式会社 薬剤的活性を有する栄養組成物
JPH01203330A (ja) * 1988-02-05 1989-08-16 Rikagaku Kenkyusho 制癌剤
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB2218904A (en) * 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
IT1230141B (it) * 1989-05-03 1991-10-14 Fidia Spa Impiego di derivati della fosfatidil carnitina per la preparazione di composizioni farmaceutiche aventi attivita' nella terapia delle patologie dell'uomo associate con un danno neuronale.
JPH03178931A (ja) * 1989-09-08 1991-08-02 Nippon Oil & Fats Co Ltd 睡眠増加剤
JPH0748992B2 (ja) * 1990-04-16 1995-05-31 日本油脂株式会社 血栓防止用粉末組成物
JP3092180B2 (ja) * 1991-02-27 2000-09-25 日本油脂株式会社 低密度リポ蛋白受容体活性化剤

Also Published As

Publication number Publication date
WO1994012170A3 (fr) 1994-07-21
FR2698269B1 (fr) 1995-01-06
CA2128706C (en) 2007-07-10
ATE192647T1 (de) 2000-05-15
DE69328618D1 (de) 2000-06-15
US5654290A (en) 1997-08-05
CA2128706A1 (en) 1994-06-09
WO1994012170A2 (fr) 1994-06-09
EP0623019A1 (fr) 1994-11-09
EP0623019B1 (fr) 2000-05-10
JPH07503488A (ja) 1995-04-13
FR2698269A1 (fr) 1994-05-27
DK0623019T3 (da) 2000-10-02
DE69328618T2 (de) 2001-02-01

Similar Documents

Publication Publication Date Title
ES2149253T3 (es) Medicamentos a base de acido docosahexaenoico como antiagregantes plaquetarios y contra las carencias cerebrales en acidos grasos esenciales y procedimientos de preparacion.
DK1121115T4 (da) PUFA-tilskud
DE60000133D1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
IT8720700A0 (it) Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e// dietetiche contenenti detti esteri.
BR0112073A (pt) Combinações terapêuticas de ácidos graxos
ES2117390T3 (es) Sales de un acido graso poliinsaturado y formulaciones farmaceuticas que las contienen.
GB2218984B (en) Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
CY1105119T1 (el) Χρηση πολυακορεστων λιπαρων οξεων για την πρωτογενη προληψη σοβαρων καρδιαγγειακων επεισοδιων
ATE236627T1 (de) Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
BR0112680A (pt) Genes elongase e usos dos mesmos
FI863976A (fi) Terapeutisk komposition.
DE69114498D1 (de) Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen.
ES2045120T4 (es) Metodo para preparar un medicamento para el tratamiento o la prevencion de la perdida de memoria.
DE3878812D1 (de) Omega-3-fettsaeuren zur behandlung von traumatischen verwundungen.
EP0302481A3 (en) Use of free fatty acids for the manufacture of a medicament for treatment of diabetes mellitus
ES2082390T3 (es) Acido gamma-linolenico para la preparacion de un medicamento para impedir la reoclusion de las arterias.
ATE228556T1 (de) An omega-3 ungesättigten fettsäuren angereicherte wachsester, ihre herstellung und verwendung
MX9203292A (es) Derivados de acidos grasos omega-3 poliinsaturados, su preparacion y aplicacion
Wenderoth Aspects of the new eicosanoid-research.).
TH15808A (th) ไทรกลีเซอไรด์ กรรมวิธีสำหรับการผลิต c-ซับสทิทิวเทดไดเอธิลีนไทรแอมีน
TH15810A (th) สูตรผสมที่มีกรดแฟททีชนิดไม่อิ่มตัว

Legal Events

Date Code Title Description
FA2A Application withdrawn

Effective date: 19941219

FG2A Definitive protection

Ref document number: 623019

Country of ref document: ES